1. Scrip
  2. >>Business

McKinsey Execs On Expanding Pharma’s Digital Push, Lessons From Amazon

 
• By Anju Ghangurde

Two McKinsey & Company executives share their views on pharma’s digital trajectory, including the role of manufacturing ‘lighthouses’ and opportunities to deploy digital and analytical tools across the entire value chain for both innovator and generic firms. They see Amazon’s playbook on leveraging digital technology as holding some interesting lessons for pharma.

Digital_Handshake
McKinsey Executives Discuss Pharma's Digital Curve • Source: Shutterstock

Pharma appears increasingly keen to embrace data science and digital technologies to drive operational and cost efficiencies across the enterprise.

There’s momentum in industry’s efforts to create manufacturing "lighthouses" - facilities that have successfully applied Fourth Industrial Revolution technologies to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Amgen’s ‘Stunning’ VESALIUS Results Could Push Repatha Into The Mainstream

 
• By Mandy Jackson

Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.

J&J Plans Educational Push After Darzalex Smoldering Myeloma Approval

 
• By Alaric DeArment

The FDA approved the anti-CD38 monoclonal antibody, a mainstay of multiple myeloma for a decade, for high-risk smoldering disease.

Lilly/Novo Get Priority Reviews For Lowering Drug Prices

 
• By Jessica Merrill

Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

More from Scrip

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Centessa’s Sleep Disorder Drug Shows Broad Potential But Faces Tough Competition

 
• By Sushmita Panda

Pivotal data next year will be key for the early-stage biotech as analysts remain divided on ORX750's potential.